A comparative study to evaluate the efficacy of 1.5% bepotastine besilate versus 0.1% olopatadine hydrochloride in allergic conjunctivitis

Dr Pranav Gupta; Dr Etti Goyal

Volume : VIII, Issue : VI, June - 2019

A comparative study to evaluate the efficacy of 1.5% bepotastine besilate versus 0.1% olopatadine hydrochloride in allergic conjunctivitis

Dr Pranav Gupta, Dr Etti Goyal

Abstract :

OBJECTIVE To compare the efficacy of 1.5% bepotastine besilate versus 0.1% olopatadine hydrochloride in patients of allergic conjunctivitis METHODS: This randomized single center study included 40 patients with allergic conjunctivitis. The patients were divided into two groups (20 patients each). Group I was treated with bepotastine besilate 1.5% twice daily and Group II with olopatadine hydrochloride 0.1% twice daily for 14 days. RESULTS: Out of 40 patients of allergic conjunctivitis, 25 were male and 15 were female. All the patients were in the age group of 18 to 45 years. Majority of the patients (57.5%) who participated in the study were living in urban area. On Day 1, the total mean score of all the parameters were comparable in both groups (p-value > 0.01). On Day 7, there was significant (p < 0.01) reduction in itching and epiphora in group I patients as compared to group II. On Day 14, these symptoms got markedly improved in Group I patients. CONCLUSION: 1.5% bepotastine besilate topical drops are better in alleviating the symptoms of allergic conjunctivitis as compared to 0.1% olopatadine topical drops